登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 公司已根据相关会计准则对与华特信息公司相关的长期股权投资、往来款项等进行了相应的会计处理， 本次华特信息公司的注销不会影响公司正常生产经营和盈利能力，有利于公司贯彻落实聚焦儿童医药健 康主业战略，进一步优化资源配置，提升整体运营效率，更好保障公司主营业务发展和投资者的长远利 益。 敬请投资者理性投资，注意投资风险。 2026年1月29日，济南市天桥区行政审批服务局出具《登记通知书》（天桥）登字[2026]第004594号， 对山东华特信息科技有限公司（以下简称"华特信息公司"）提交的注销登记申请予以登记。华特信息公 司破产清算及市场主体注销登记程序已办理完成。 一、华特信息公司破产清算情况 华特信息公司原为山东华特达因健康股份有限公司（以下简称"公司"）全资子公司。公司于 2023 年 10 月20日在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于公司全资子公司山东华特信息科技有限 公司申请破产清算的公告》（公告编号： 2023-029 ...

Financial Performance - The company achieved a revenue of 1.17 billion CNY in the first half of 2025, representing a year-on-year growth of 1.39% [2] - Net profit attributable to shareholders reached 337 million CNY, with a growth of 1.69% year-on-year, resulting in a net profit margin of 98.6% [2] - The net cash flow from operating activities was 674 million CNY, showing a significant increase of 61.44% compared to the previous year [2] Product Development and Market Strategy - The company focused on children's pharmaceuticals, with a strong emphasis on product development and brand extension, including new registrations for oral solutions and clinical trials for aerosol products [2] - The brand "Yike Xin" maintained a strong market presence, contributing approximately 79% to total revenue, with a sales ratio of 1.6:1 between different product lines [3][4] - Online sales accounted for 25% of total revenue, with significant growth driven by marketing reforms and the establishment of a new retail division [5][4] Brand Value and Marketing Initiatives - The brand value of "Yike Xin" was assessed at 23.126 billion CNY, ranking among the "2025 China Brand 500" [2] - The company engaged in various promotional activities, including marathons and family-oriented events, to enhance brand recognition and consumer engagement [3] Governance and Shareholder Engagement - The company completed a management restructuring, adding three new senior executives from within the organization to strengthen operational management [3] - A proposed dividend of 25 CNY per 10 shares for the 2024 fiscal year was announced, with a dividend yield exceeding 7% [3][9] Future Outlook - The company anticipates continued growth in online sales and plans to expand its product offerings in the children's health sector, particularly in response to government policies supporting child health and nutrition [6][11] - The introduction of new products, including melatonin granules, is expected to fill market gaps and leverage the company's established brand influence [7][10]